<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39468707</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2150-5608</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Virulence</Title><ISOAbbreviation>Virulence</ISOAbbreviation></Journal><ArticleTitle>The characteristics of TCR CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccine recipients.</ArticleTitle><Pagination><StartPage>2421987</StartPage><MedlinePgn>2421987</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21505594.2024.2421987</ELocationID><Abstract><AbstractText>The COVID-19 pandemic and large-scale administration of multiple SARS-CoV-2 vaccines have attracted global attention to the short-term and long-term effects on the human immune system. An analysis of the "traces" left by the body's T-cell immune response is needed, especially for the prevention and treatment of breakthrough infections and long COVID-19 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infections. T-cell receptor complementarity determining region 3 (TCR CDR3) repertoire serves as a target molecule for monitoring the effects, mechanisms, and memory of the T-cell response. Furthermore, it has been extensively applied in the elucidation of the infectious mechanism and vaccine refinement of hepatitis B virus (HBV), influenza virus, human immunodeficiency virus (HIV), and SARS-CoV. Laboratories worldwide have utilized high-throughput sequencing (HTS) and scTCR-seq to characterize, share, and apply the TCR CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccine recipients. This article focuses on the comparative analysis of the diversity, clonality, V&amp;J gene usage and pairing, CDR3 length, shared CDR3 sequences or motifs, and other characteristics of TCR CDR3 repertoire. These findings provide molecular targets for evaluating T-cell response effects and short-term and long-term impacts on the adaptive immune system following SARS-CoV-2 infection or vaccination and establish a comparative archive of T-cell response "traces."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Dewei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Center of Immunomolecular Engineering, Innovation &amp; Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Laboratory, The First People's Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University), Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunology, Center of Immunomolecular Engineering, Innovation &amp; Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Central laboratory, Guizhou Aerospace Hospital, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunology, Center of Immunomolecular Engineering, Innovation &amp; Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xinsheng</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6960-4003</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Center of Immunomolecular Engineering, Innovation &amp; Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virulence</MedlineTA><NlmUniqueID>101531386</NlmUniqueID><ISSNLinking>2150-5594</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword><Keyword MajorTopicYN="N">Single-cell TCR sequencing</Keyword><Keyword MajorTopicYN="N">TCR CDR3 repertoire</Keyword><Keyword MajorTopicYN="N">high-throughput sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468707</ArticleId><ArticleId IdType="doi">10.1080/21505594.2024.2421987</ArticleId></ArticleIdList></PubmedData></PubmedArticle>